Table 1.
Clinical characteristics of participants
| Healthy | Adjuvant | Metastatic | T-Naive | |
|---|---|---|---|---|
| Number, N |
28 |
13 |
15 |
15 |
| Age, years | ||||
| Median |
30 |
58 |
68 |
64 |
| Range |
23-55 |
37-82 |
40-75 |
34-74 |
| HER2/neu receptor, N (%) | ||||
| Positive |
N.A. |
13 (100%) |
15 (100%) |
0 (0%) |
| Negative |
|
0 (0%) |
0 (0%) |
15 (100%) |
| Estrogen receptor, N (%) | ||||
| Positive |
N.A. |
9 (69%) |
8 (44%) |
11 (70%) |
| Negative |
|
4 (31%) |
7 (46%) |
4 (30%) |
| Progesterone receptor, N (%) | ||||
| Positive |
N.A. |
5 (38%) |
1 (10%) |
7 (40%) |
| Negative |
|
8 (62%) |
14 (90%) |
8 (60%) |
| Trastuzumab, N |
N.A. |
13 (100%) |
15 (100%) |
N.A. |
| Median application time, months |
|
7 |
58 |
|
| IQR |
|
5 |
45 |
|
| Chemotherapy, N (%) | ||||
| FEC |
N.A. |
1 (10%) |
|
1 (10%) |
| FEC-Doc |
|
|
|
1 (10%) |
| EC |
|
|
|
3 (20%) |
| EC-D |
|
|
|
2 (10%) |
| CMF |
|
1 (10%) |
|
|
| Docetaxel + Epirubicin |
|
3 (20%) |
1 (10%) |
|
| Docetaxel |
|
1 (10%) |
|
|
| Vinorelbin |
|
1 (10%) |
1 (10%) |
|
| Carboplatin |
|
|
1 (10%) |
|
| Paclitaxel | 1 (10%) | |||
N: number of individuals; N.A.: not applicable; IQR: Interquartile range; FEC: 5-Fluorouracil, Epirubicin and Cyclophosphamide; FEC-Doc: 5-Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel; EC: Epirubicin and Cyclophosphamide; EC-D: Epirubicin, Cyclophosphamide and Docetaxel; CMF: Cyclophosphamide, Methotrexate and 5-Fluorouracil.